Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Boxun Biotech (920504) experienced a net sell-off of 300,800 yuan by speculative funds on March 26.
According to Securities Star, as of the market close on March 26, 2026, Boshun Bio (920504) closed at 21.05 yuan, down 1.17%, with a turnover rate of 1.39%, a trading volume of 2,378.0 lots, and a transaction amount of 5.0799 million yuan.
On March 26, the capital flow data showed no net inflow of institutional funds, with retail funds having a net outflow of 300,800 yuan, accounting for 5.92% of the total transaction amount, and individual investors having a net outflow of 3,300 yuan, accounting for 0.06% of the total transaction amount.
Boshun Bio’s 2025 Q3 report shows that in the first three quarters, the company’s main revenue was 84.5761 million yuan, an increase of 0.43% year-on-year; the net profit attributable to the parent company was 8.5438 million yuan, an increase of 4.5% year-on-year; the net profit excluding non-recurring gains and losses was 6.9786 million yuan, a decrease of 0.87% year-on-year; in the third quarter of 2025, the company reported a single-quarter main revenue of 32.0607 million yuan, an increase of 12.81% year-on-year; a single-quarter net profit attributable to the parent company of 4.9074 million yuan, an increase of 14.39% year-on-year; a single-quarter net profit excluding non-recurring gains and losses of 4.0309 million yuan, an increase of 4.32% year-on-year; the debt ratio was 21.57%, with investment income of 1.0727 million yuan, financial expenses of -42,500 yuan, and a gross profit margin of 41.13%. Boshun Bio (920504) is engaged in the research and development, production, sales, and service of laboratory equipment and life science instruments.
Definition of capital flow: Refers to inferring capital flow through price changes. When the stock price is rising, the transaction amount generated by active buy orders is the driving force behind the stock price increase, and this transaction amount is defined as capital inflow. When the stock price is falling, the transaction amount generated by active sell orders is the driving force behind the stock price decrease, and this transaction amount is defined as capital outflow. The difference between the two on that day is the net force that remains to push the stock price up after the two forces counteract each other. The capital flow of institutional funds, retail funds, and individual investors is calculated based on the transaction amount of each trade.
Note: Institutional funds are defined as large transactions, retail funds as medium transactions, and individual investors as small transactions.
The above content is organized by Securities Star based on public information and generated by AI algorithms (Internet Information Office filing number 310104345710301240019), and does not constitute investment advice.